Search Result

Results for "

BP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (12) ATM/ATR (2) Autophagy (17) Bacterial (7) Biochemical Assay Reagents (5) Calcium Channel (16) Casein Kinase (1) CDK (2) CRFR (3) DNA/RNA Synthesis (2) Dopamine Receptor (2) Endogenous Metabolite (1) FAP (1) Fluorescent Dye (5) Hexokinase (1) HSP (1) HSV (1) IFNAR (1) Insulin Receptor (2) Integrin (4) Interleukin Related (2) Isotope-Labeled Compounds (5) Liposome (23) Mitophagy (2) mTOR (4) nAChR (1) Neprilysin (1) Organoid (2) p38 MAPK (2) p97 (1) PDGFR (1) Pim (1) PROTACs (1) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (1) Small Interfering RNA (siRNA) (37) Sodium Channel (7) STAT (4) STING (3) VEGFR (2)
By Research Areas:	Cancer (77) Cardiovascular Disease (22) Endocrinology (1) Infection (7) Inflammation/Immunology (9) Metabolic Disease (10) Neurological Disease (15)
Click Chemistry:	Labeling and Fluorescence Imaging (1) Alkynes (1)
Oligonucleotides:	Aptamers (1) Pre-designed siRNA Sets (37) Cationic Lipids (23) Antisense Oligonucleotides (2) siRNAs (37)

151

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106660

BP 897 hydrochloride	Dopamine Receptor	Neurological Disease
BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-100493

BP-1-102 5+ Cited Publications	STAT	Cancer
BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

HY-W440779

BP Lipid 135	Liposome	Metabolic Disease
BP Lipid 135 is a cationieally ionizable lipid. BP Lipid 135 can be used to prepare lipid nanoparticles (LNP) (WO2022218503A1) .

HY-125151

BP-1-108	STAT Apoptosis	Cancer
BP-1-108 is a selective inhibitor of STAT5 (K_i=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer .

HY-109743

BP14979	Others	Neurological Disease
BP14979 is a dopamine D3 receptor agonist with activity in the study of neurological diseases. BP14979 can be used to develop ligands with higher selectivity and affinity for D3 receptors. The structural characteristics of BP14979 make it potential in modulating the efficacy of D3 receptors. The design of BP14979 is based on the difference in efficacy with D3R selective antagonists, providing opportunities for optimizing new drug development .

HY-136797

BP13944	Others	Infection
BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.

HY-114085

BP 897	Dopamine Receptor	Neurological Disease
BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-158865

BP Lipid 399	Liposome	Others
BP Lipid 399 is derived from patent WO2020219876A1 (Example 3).BP Lipid 399 is an ionizable amino lipid analog of LP01 featuring a novel pyrrolidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.

HY-157850

BP-M345	Others	Cancer
BP-M345 (compound 5) is a potent, cancer cell-targeting antiproliferative agent that exhibits low toxicity to non-tumor cells. BP-M345 inhibits cancer cell proliferation with a GI₅₀ value ranging from 0.17 to 0.45 μM .

HY-W800802

BP Lipid 227	Liposome	Cancer
BP Lipid 227 is an ionizable lipid. It has primary esters at C5 position relative to the amine nitrogen. The primary lipid tail has an 8 carbon tail. BP Lipid 227 can be used in the generation of liposomes.

HY-W800827

BP Lipid 229	Liposome	Cancer
BP Lipid 229 is an amino ionizable lipid. It has primary esters at C7 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. BP Lipid 229 can be used in the generation of liposomes.

HY-158866

BP Lipid 401	Liposome	Others
BP Lipid 401 is derived from patent WO2020219876A1 (Example 102). BP Lipid 401 features a unique piperidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.

HY-W440753

BP Lipid 114	Liposome	Others
BP Lipid 114 is an ethanolamine ionizable lipid (CN113387825A) .

HY-158864

BP Lipid 378	Liposome	Others
BP Lipid 378 is derived from patent WO2020219876A1 (Example 8). BP Lipid 378 is an ionizable amino lipid that features a unique pyrrolidine head group with a carbamate linkage to the lipid tails. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.

HY-158863

BP Lipid 377	Liposome	Others
BP Lipid 377 is derived from patent WO2018062413A1. BP Lipid 377 is an ionizable amino lipid comprised of three linoleic acid tails and an N,N-dimethylamine head group four carbon atoms in length. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA and drug delivery.

HY-W440802

BP Lipid 217	Liposome	Others
BP Lipid 217 is derived from patent WO2023178065A2 (B32). BP Lipid 217 is an ethanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.

HY-W800737

BP Lipid 126	Liposome	Cancer
BP Lipid 126 is an amino ionizable lipid (Compound 143) from patent WO2017201333A1 with ester bonds located at C8 and C7 position relative to nitrogen. The ester linkages are introduced to improve tissue clearance. The ethanolamine head can effectively enhance mRNA encapsulation. BP Lipid 126 can be used in the generation of liposomes.

HY-W440752

BP Lipid 113	Liposome	Cancer
BP Lipid 113 is an ionizable lipid analogous to SM-102. It can be used to prepare liposome or lipid nanoparticles.

HY-W440803

BP Lipid 218	Liposome	Cancer
BP Lipid 218 is an ionizable amine lipid with two identical ester tails adjacent to C6 position relative to amine.

HY-W440743

BP Lipid 103	Liposome	Cancer
BP Lipid 103 is an amine ionizable lipid analogous to SM-102. It can be used to prepare liposome or lipid nanoparticles.

HY-W440800

BP Lipid 226	Liposome	Cancer
BP Lipid 226 is an amino ionizable lipid analogous to ALC-0315. It can be used to prepare liposome or lipid nanoparticles.

HY-W800841

BP Lipid 314	Liposome	Cancer
BP Lipid 314 is an ionizable amino lipid featuring a dimethylamino head group, a carbamate linking to a central tertiary carbon with two other branches, a linoleate ester, and an aliphatic acetal ester.

HY-114941

Aladotril BP1137	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .

HY-W440787

BP Lipid 142	Liposome	Others
BP Lipid 142 is derived from patent WO2018170306A1 (Example 102). BP Lipid 142 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 and C8 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The primary ester located at C6 is attached with a long (11-carbon) lipid tail. The lipid can be used for mRNA-based therapies.

HY-W800812

BP Lipid 308	Liposome	Cancer
BP Lipid 308 has a terminal tertiary amine group, a linoleic group, and a 4,4-bis(octyloxy)butanoic acid sodium salt tail. This compound can be useful for the building or modification of lipid nanoparticles.

HY-158862

BP Lipid 376	Liposome	Others
BP Lipid 376 features a unique piperidine ionizable head group with a carbamate linkage to the lipid scaffold comprised of a linoleate ester and aliphatic acetal ester. This lipid may be used in the development of lipid nanoparticles for drug delivery.

HY-W440751

BP Lipid 112	Liposome	Cancer
BP Lipid 112 is an amine lipid with two ester linkages at C6 and C7 position. The C6 ester has a long 11 carbons lipid tail. It can be used to prepare liposome or lipid nanoparticles.

HY-W440748

BP Lipid 109	Liposome	Cancer
BP Lipid 109 is an amine lipid which has long (11 carbons) lipid tail on the primary ester. Both esters are located at C7 position and the head contains ethanolamine. It can be used to prepare liposome or lipid nanoparticles.

HY-W440766

BP Lipid 209	Liposome	Cancer
BP Lipid 209 is an amine lipid which has a 9-carbons lipid tail on the primary ester. Both esters are located at C8 and C10 position relative to the amine nitrogen. It can be used to prepare liposome or lipid nanoparticles.

HY-W800849

BP Lipid 315	Liposome	Cancer
BP Lipid 315 is a cationic ionizable lipid ALC-0315 analogue featuring a Boc-protected primary amine, a central tertiary amine, and two ester tails located at the C8 position relative to the amine. One of these esters features a symmetrical branched C17 tail, while the other is an asymmetric C11 tail.

HY-W800749

BP Lipid 223	Liposome	Cancer
BP Lipid 223 is an pentanolamine lipid (Compound 7) from patent WO2017075531A with both ester bonds located adjacent to C6 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile.

HY-19470

Topilutamide 1 Publications Verification BP766; Fluridil	Androgen Receptor	Cancer
Topilutamide is a topical nonsteroidal antiandrogen (NSAA).

HY-N0848

Epibrassinolide 10+ Cited Publications 24-Epibrassinolide; B1105; BP55	Apoptosis	Cancer
Epibrassinolide (24-Epibrassinolide) is a ubiquitously occurring plant growth hormone which shows great potential to alleviate heavy metals and pesticide stress in plants . Epibrassinolide is a potential apoptotic inducer in various cancer cells without affecting the non-tumor cell growth .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment .

HY-156110

IGF2BP1-IN-1	Insulin Receptor	Cancer
IGF2BP1-IN-1 (Compound A11) is a *IGF2BP1* inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a K_D value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC₅₀: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model .

HY-D1418

CP-BP-SFAC	Fluorescent Dye	Others
CP-BP-SFAC is a luminogenic molecule. CP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films .

HY-D1417

P-BP-SFAC	Fluorescent Dye	Others
P-BP-SFAC is a fluorescence molecule. P-BP-SFAC exhibits an apparent absorption band with a peak at about 377 nm, indicative of a stronger ICT effect .

HY-P6010

αvβ6-BP	Integrin	Cancer
αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .

HY-110087

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 nAChR. 4BP-TQS activates nAChRs via an allosteric transmembrane site .

HY-P6009

Cys-αvβ6-BP	Integrin	Cancer
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .

HY-P6010A

αvβ6-BP TFA	Integrin	Cancer
αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .

HY-D1419

mCP-BP-SFAC	Fluorescent Dye	Others
mCP-BP-SFAC is a luminogenic molecule. mCP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films, with photoluminescence (PL) peaks at ~483 nm and delayed fluorescence lifetimes of 5.4 to 5.7 μs .

HY-D1420

TCP-BP-SFAC	Fluorescent Dye	Others
TCP-BP-SFAC is a luminogenic molecule. TCP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films, with photoluminescence (PL) peaks at ~483 nm and delayed fluorescence lifetimes of 5.4 to 5.7 μs .

HY-P6009A

Cys-αvβ6-BP TFA	Integrin	Cancer
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-U00035

MGB-BP-3	Bacterial	Infection
MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens.

HY-RS00101

ABI3BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABI3BP Human Pre-designed siRNA Set A contains three designed siRNAs for ABI3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABI3BP Human Pre-designed siRNA Set A ABI3BP Human Pre-designed siRNA Set A

HY-RS00986

ARL2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ARL2BP Human Pre-designed siRNA Set A contains three designed siRNAs for ARL2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ARL2BP Human Pre-designed siRNA Set A ARL2BP Human Pre-designed siRNA Set A

HY-RS14095

SYNJ2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SYNJ2BP Human Pre-designed siRNA Set A contains three designed siRNAs for SYNJ2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYNJ2BP Human Pre-designed siRNA Set A SYNJ2BP Human Pre-designed siRNA Set A

HY-RS06410

HSF2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HSF2BP Human Pre-designed siRNA Set A contains three designed siRNAs for HSF2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HSF2BP Human Pre-designed siRNA Set A HSF2BP Human Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0848

Epibrassinolide 10+ Cited Publications 24-Epibrassinolide; B1105; BP55	Structural Classification Natural Products Classification of Application Fields Source classification Plants Biological Pesticide Research Agricultural Research Brassinolide Phytohormone Brassicaceae Brassica campestris L. Disease Research Fields Cancer	Apoptosis
Epibrassinolide (24-Epibrassinolide) is a ubiquitously occurring plant growth hormone which shows great potential to alleviate heavy metals and pesticide stress in plants . Epibrassinolide is a potential apoptotic inducer in various cancer cells without affecting the non-tumor cell growth .

HY-N0252

Catharanthine (+)-3,4-Didehydrocoronaridine	Apocynaceae Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity .

HY-N0252A

Catharanthine Tartrate (+)-3,4-Didehydrocoronaridine Tartrate	Apocynaceae Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don Cancer	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine) Tartrate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine Tartrate has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Tartrate lowers blood pressure (BP), heart rate (HR). Catharanthine Tartrate has anti-cancer activity .

HY-N6954

Garcinone C 1 Publications Verification	Structural Classification other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	ATM/ATR STAT CDK
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3* and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner .

HY-P1974

FR 901379 WF11899A	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

HY-N0252B

Catharanthine Sulfate (+)-3,4-Didehydrocoronaridine Sulfate	Cardiovascular Disease Apocynaceae Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine) Sulfate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine Sulfate has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Sulfate lowers blood pressure (BP), heart rate (HR). Catharanthine Sulfate has anti-cancer activity .

HY-N0252R

Catharanthine (Standard)	Apocynaceae Alkaloids Structural Classification Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine (Standard) is the analytical standard of Catharanthine. This product is intended for research and analytical applications. Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca2+ channel (VOCC). Catharanthine has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity .

HY-N6954R

Garcinone C (Standard)	Structural Classification other families Xanthones Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants	ATM/ATR STAT CDK
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time? and dose?dependent manner .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0309S2

Felodipine-d3
Felodipine-d₃ is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-13777S

Zoledronic acid-d5
Zoledronic acid-d₅ is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-B0309S1

Felodipine-d5
Felodipine-d₅ is deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

HY-132670S

(R)-(-)-Felodipine-d5

(R)-(-)-Felodipine-d₅ is the deuterium labeled (R)-(-)-Felodipine. (R)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks